Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

International rare cancers initiative multicenter randomized phase II trial of cisplatin and fluorouracil cersus carboplatin and paclitaxel in advanced anal cancer: InterAAct

Rao, Sheela, Sclafani, Francesco, Eng, Cathy, Adams, Richard A., Guren, Marianne G., Sebag-Montefiore, David, Benson, Al, Bryant, Annette, Peckitt, Clare, Segelov, Eva, Roy, Amitesh, Seymour, Matt T., Welch, Jack, Saunders, Mark P., Muirhead, Rebecca, O'Dwyer, Peter, Bridgewater, John, Bhide, Shree, Glynne-Jones, Rob, Arnold, Dirk and Cunningham, David 2020. International rare cancers initiative multicenter randomized phase II trial of cisplatin and fluorouracil cersus carboplatin and paclitaxel in advanced anal cancer: InterAAct. Journal of Clinical Oncology 38 (22) , pp. 2510-2518. 10.1200/JCO.19.03266

Full text not available from this repository.

Abstract

PURPOSE To compare cisplatin plus fluorouracil (FU) versus carboplatin plus paclitaxel in chemotherapy-naïve advanced anal cancer to establish the optimal regimen. PATIENTS AND METHODS Patients who had not received systemic therapy for advanced anal cancer were randomly assigned 1:1 to intravenous cisplatin 60 mg/m2 (day 1) plus FU 1,000 mg/m2 (days 1-4) every 21 days or carboplatin (area under the curve, 5; day 1) plus paclitaxel 80 mg/m2 (days 1, 8, and 15) every 28 days for 24 weeks, until disease progression, intolerable toxicity, or withdrawal of consent. Primary end point was objective response rate (ORR). Primary and secondary end points were assessed in a hierarchic model to compare the regimens and pick the winner. RESULTS We conducted an international multicenter randomized phase II study in 60 centers between December 2013 and November 2017. Median follow-up was 28.6 months. A total of 91 patients were randomly assigned: 46 to cisplatin plus FU and 45 to carboplatin plus paclitaxel. ORR was 57% (95% CI, 39.4% to 73.7%) for cisplatin plus FU versus 59% (95% CI, 42.1% to 74.4%) for carboplatin plus paclitaxel. More serious adverse events were noted in the cisplatin plus FU arm (62%) compared with the carboplatin plus paclitaxel arm (36%; P = .016). Median progression-free survival was 5.7 months (95% CI, 3.3 to 9.0 months) for cisplatin plus FU compared with 8.1 months (95% CI, 6.6 to 8.8 months) for carboplatin plus paclitaxel. Median overall survival was 12.3 months for cisplatin plus FU (95% CI, 9.2 to 17.7 months) compared with 20 months (95% CI, 12.7 months to not reached) for carboplatin plus paclitaxel (hazard ratio, 2.00; 95% CI, 1.15 to 3.47; P = .014). CONCLUSION This is the first international randomized trial to our knowledge conducted in chemotherapy-naïve advanced anal cancer. Although there was no difference in ORR, the association with clinically relevant reduced toxicity and a trend toward longer survival suggest that carboplatin plus paclitaxel should be considered as a new standard of care.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Centre for Trials Research (CNTRR)
Publisher: American Society of Clinical Oncology
ISSN: 0732-183X
Last Modified: 13 May 2021 15:30
URI: https://orca.cardiff.ac.uk/id/eprint/141035

Citation Data

Cited 46 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item